![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Oncodesign, a contract research laboratory for the discovery of new anticancer therapies, today announces that its Dijon-based research center has received AAALAC certification.
AAALAC, the Association for Assessment and Accreditation of Laboratory Animal Care International, is an internationally recognized association for assessment and accreditation in the field of animal experimentation. AAALAC accreditation is a voluntary undertaking rather than a regulatory requirement. To date, more than 700 institutions in 29 countries have received this accreditation.
From the foundation of the company, Oncodesign has combined a rigorous scientific approach with leading-edge methods to deliver more valuable results, minimizing dependence on animal experimentation by developing in vitro biological models of cancer and non-invasive procedures. It also uses sophisticated in vivo imaging technologies (such as PET scanning, MRI, SPECT and ultrasound). These methods are used to study the impact of new treatments on tumor tissue and organs. Oncodesign makes use of experimental models that have been developed using tumor samples taken directly from patients. Continued investment in training research teams, new infrastructures and founding both an in-house ethics committee and a category A2 experimental research zone all demonstrate Oncodesign’s focus on conducting high value-added research.
Oncodesign complies with all the applicable legislation, specifically the European Convention on animals used for experimental purposes (ETS 123) and the US Ministry of Agriculture’s regulations relating to animal well-being (NRC 2011). This also applies to Oncodesign’s external partners and research agencies.
“AAALAC accreditation is both an endorsement and a significant acknowledgment of Oncodesign’s skills and expertise and the credibility of its scientific work,” said Philippe Genne, Ph.D., chairman, CEO and founder of Oncodesign. “AAALAC accreditation underlines the company’s efforts to contribute to progressing research programs and improving experimental best practice on the international stage. By meeting the highest standards in the field, Oncodesign is able to provide an additional level of ethical and quality assurance, both of which play a major part in widening its target client base.”
About Oncodesign
Founded in 1995 and headed by Dr. Philippe Genne, Oncodesign is a pioneer in the preclinical assessment of anti-cancer therapies, a market in which it has been leading for many years. Oncodesign’s mission consists of discovering effective anti-cancer therapies. Its scientific expertise in pharmacology, imaging and medicinal chemistry, in addition to strong project management skills, support the company’s two strategic activities of experimentation and discovery. These strategic activities are organized in four technological platforms and enable Oncodesign to offer a unique and innovative translational research approach conducted in partnership with pharmaceutical and biotechnology companies.
For more information, see: http://www.oncodesign.com
About AAALAC
AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. AAALAC stands for the “Association for Assessment and Accreditation of Laboratory Animal Care.”
AAALAC endorses the use of animals to advance medicine and science when there are no non-animal alternatives and when it is done in an ethical and humane way. When animals are used, AAALAC works with institutions and researchers to serve as a bridge between progress and animal well-being. This is done through AAALAC’s voluntary accreditation process in which research programs demonstrate that they meet the minimum standards required by law and are going the extra step to achieve excellence in animal care and use. In this way, AAALAC International is where science and responsible animal care connect.
